Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014748:Vinca Alkaloids / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D014748:Vinca Alkaloids; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D002330:Carmustine; D011241:Prednisone; D008727:Methotrexate